Development and Validation of a Fourteen- Innate Immunity-related Gene Pairs Signature for Predicting Prognosis Head and Neck Squamous Cell Carcinoma

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2020 Oct 21

PMID 33081731

Citations 20

Authors

Fujun Zhang

Yu Liu

Yixin Yang

Kai Yang

Affiliations

Soon will be listed here.

Abstract

Background: Immune-related genes is closely related to the occurrence and prognosis of head and neck squamous cell carcinoma (HNSCC). At the same time, immune-related genes have great potential as prognostic markers in many types of cancer. The prognosis of HNSCC is still poor currently, and it may be effective to predict the clinical outcome of HNSCC by immunogenic analysis.

Methods: RNASeq and clinical follow-up information were downloaded from The Cancer Genome Atlas (TCGA), the MINiML format GSE65858 chip expression data was downloaded from NCBI, and immune-related genes was downloaded from the InnateDB database. Immune-related genes in 519 HNSC patients were integrated from TCGA dataset. By using multivariate COX analysis and Lasso regression, robust immune-related gene pairs (IRGPs) that predict clinical outcomes of HNSCC were identified. Finally, a risk prognostic model related to immune gene pair was established and verified by clinical features, test sets and GEO external validation set.

Results: A total of 699 IRGPs were significantly correlated with the prognosis of HNSCC patients. Fourteen robust IRGPs were finally obtained by Lasso regression and a prognostic risk prediction model was constructed. Risk score of each sample were calculated based on Risk models and divided into the high-risk group (Risk-H) and low Risk group (Risk-L). Risk models were able to stratify the risk in patients with TNM Stage, Age, gender, and smoking history, and the AUC > 0.65 in training set and test set, shows that 14-IRGPs signature in patients with HNSCC has excellent classification performance. In addition, 14-IRGPs had the highest average C index compared with the prognostic characteristics and T, N, and Age of the 3 previously reported HNSCC.

Conclusion: This study constructed 14-IRGPs as a novel prognostic marker for predicting survival in HNSCC patients.

Citing Articles

Neoadjuvant Immunotherapy in Head and Neck Cancers: A Paradigm Shift in Treatment Approach.

Zotta A, Marciano M, Sabbatino F, Ottaiano A, Cascella M, Pontone M Biomedicines. 2024; 12(10).

PMID: 39457649 PMC: 11505575. DOI: 10.3390/biomedicines12102337.

Deciphering COPS5 influence on immune infiltration and prognosis in head and neck squamous cell carcinoma.

Wan Y, Wang D, Yang G, Liu G, Pan Y Heliyon. 2024; 10(13):e33553.

PMID: 39040236 PMC: 11261772. DOI: 10.1016/j.heliyon.2024.e33553.

Patients with oral tongue squamous cell carcinoma and co‑existing diabetes exhibit lower recurrence rates and improved survival: Implications for treatment.

Salehi A, Wang L, Gu X, Coates P, Norberg Spaak L, Sgaramella N Oncol Lett. 2024; 27(4):142.

PMID: 38385115 PMC: 10877229. DOI: 10.3892/ol.2024.14275.

A novel immune-related prognostic model with surgical status to predict tumor immune cell infiltration and drug sensitivity in head and neck squamous cell carcinoma.

Wang L, Yu X, Li H, Wang C Biochem Biophys Rep. 2023; 36:101557.

PMID: 37868302 PMC: 10585349. DOI: 10.1016/j.bbrep.2023.101557.

Systematic analysis of expression and prognostic significance for MCM family in head and neck squamous cell carcinoma.

Sun E, Peng L, Liu Z, Yan Z, Chen M, Zheng J Histol Histopathol. 2023; 39(4):471-482.

PMID: 37526267 DOI: 10.14670/HH-18-652.

References

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

Cao R, Wu Q, Li Q, Yao M, Zhou H . A 3-mRNA-based prognostic signature of survival in oral squamous cell carcinoma. PeerJ. 2019; 7:e7360. PMC: 6679650. DOI: 10.7717/peerj.7360. View

Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov J . Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011; 27(12):1739-40. PMC: 3106198. DOI: 10.1093/bioinformatics/btr260. View

Yuan Y, Van Allen E, Omberg L, Wagle N, Amin-Mansour A, Sokolov A . Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nat Biotechnol. 2014; 32(7):644-52. PMC: 4102885. DOI: 10.1038/nbt.2940. View

Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D . Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep. 2017; 18(1):248-262. DOI: 10.1016/j.celrep.2016.12.019. View

Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P . Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013; 122(22):3616-27. PMC: 3837510. DOI: 10.1182/blood-2013-08-518886. View

Chen L, Diao L, Yang Y, Yi X, Rodriguez B, Li Y . CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discov. 2018; 8(9):1156-1175. PMC: 6205194. DOI: 10.1158/2159-8290.CD-17-1033. View

Sherman B, Huang D, Tan Q, Guo Y, Bour S, Liu D . DAVID Knowledgebase: a gene-centered database integrating heterogeneous gene annotation resources to facilitate high-throughput gene functional analysis. BMC Bioinformatics. 2007; 8:426. PMC: 2186358. DOI: 10.1186/1471-2105-8-426. View

Rautava J, Syrjanen S . Biology of human papillomavirus infections in head and neck carcinogenesis. Head Neck Pathol. 2012; 6 Suppl 1:S3-15. PMC: 3394166. DOI: 10.1007/s12105-012-0367-2. View

10.

Friedman J, Hastie T, Tibshirani R . Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010; 33(1):1-22. PMC: 2929880. View

11.

Weed D, Zilio S, Reis I, Sargi Z, Abouyared M, Gomez-Fernandez C . The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial. Front Immunol. 2019; 10:1206. PMC: 6554471. DOI: 10.3389/fimmu.2019.01206. View

12.

Wu J, Zhao Y, Zhang J, Wu Q, Wang W . Development and validation of an immune-related gene pairs signature in colorectal cancer. Oncoimmunology. 2019; 8(7):1596715. PMC: 6527298. DOI: 10.1080/2162402X.2019.1596715. View

13.

Forster M, Devlin M . Immune Checkpoint Inhibition in Head and Neck Cancer. Front Oncol. 2018; 8:310. PMC: 6123367. DOI: 10.3389/fonc.2018.00310. View

14.

Kostareli E, Hielscher T, Zucknick M, Baboci L, Wichmann G, Holzinger D . Gene promoter methylation signature predicts survival of head and neck squamous cell carcinoma patients. Epigenetics. 2016; 11(1):61-73. PMC: 4846111. DOI: 10.1080/15592294.2015.1137414. View

15.

Popovic A, Jaffee E, Zaidi N . Emerging strategies for combination checkpoint modulators in cancer immunotherapy. J Clin Invest. 2018; 128(8):3209-3218. PMC: 6063475. DOI: 10.1172/JCI120775. View

16.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View

17.

Posner M, Vermorken J . Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer. Semin Oncol. 2008; 35(3):221-8. DOI: 10.1053/j.seminoncol.2008.03.007. View

18.

Han J, Chen M, Wang Y, Gong B, Zhuang T, Liang L . Identification of Biomarkers Based on Differentially Expressed Genes in Papillary Thyroid Carcinoma. Sci Rep. 2018; 8(1):9912. PMC: 6028435. DOI: 10.1038/s41598-018-28299-9. View

19.

Kobold S, Pantelyushin S, Rataj F, Vom Berg J . Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy. Front Oncol. 2018; 8:285. PMC: 6068270. DOI: 10.3389/fonc.2018.00285. View

20.

Li B, Cui Y, Diehn M, Li R . Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer. JAMA Oncol. 2017; 3(11):1529-1537. PMC: 5710196. DOI: 10.1001/jamaoncol.2017.1609. View